Martin Glennie
Martin Glennie
Verified email at - Homepage
Cited by
Cited by
Guidelines for the welfare and use of animals in cancer research
P Workman, EO Aboagye, F Balkwill, A Balmain, G Bruder, DJ Chaplin, ...
British journal of cancer 102 (11), 1555-1577, 2010
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling, RR French, MS Cragg, J van den Brakel, M Pluyter, H Huang, ...
Blood 104 (6), 1793-1800, 2004
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
JL Teeling, WJM Mackus, LJJM Wiegman, JHN van den Brakel, SA Beers, ...
The Journal of Immunology 177 (1), 362-371, 2006
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ...
Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003
Immunostimulatory monoclonal antibodies for cancer therapy
I Melero, S Hervas-Stubbs, M Glennie, DM Pardoll, L Chen
Nature Reviews Cancer 7 (2), 95-106, 2007
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg, MJ Glennie
Blood 103 (7), 2738-2743, 2004
Mechanisms of killing by anti-CD20 monoclonal antibodies
MJ Glennie, RR French, MS Cragg, RP Taylor
Molecular immunology 44 (16), 3823-3837, 2007
CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
RR French, HT Chan, AL Tutt, MJ Glennie
Nature medicine 5 (5), 548-553, 1999
The biology of CD20 and its potential as a target for mAb therapy
MS Cragg, CA Walshe, AO Ivanov, MJ Glennie
B cell trophic factors and B cell antagonism in autoimmune disease 8, 140-174, 2005
Clinical trials of antibody therapy
MJ Glennie, PWM Johnson
Immunology today 21 (8), 403-410, 2000
Agonistic CD40 antibodies and cancer therapy
RH Vonderheide, MJ Glennie
Clinical Cancer Research 19 (5), 1035-1043, 2013
Preparation and performance of bispecific F (ab'gamma) 2 antibody containing thioether-linked Fab'gamma fragments.
MJ Glennie, HM McBride, AT Worth, GT Stevenson
Journal of immunology (Baltimore, Md.: 1950) 139 (7), 2367-2375, 1987
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ...
Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010
The mechanisms of action of rituximab in the elimination of tumor cells
P Johnson, M Glennie
Seminars in oncology 30 (1), 3-8, 2003
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
W Alduaij, A Ivanov, J Honeychurch, EJ Cheadle, S Potluri, SH Lim, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4519-4529, 2011
Anti-CD20 monoclonal antibodies: historical and future perspectives
SH Lim, SA Beers, RR French, PWM Johnson, MJ Glennie, MS Cragg
haematologica 95 (1), 135, 2010
Trispecific F (ab') 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
A Tutt, GT Stevenson, MJ Glennie
Journal of immunology (Baltimore, Md.: 1950) 147 (1), 60-69, 1991
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
SH Lim, AT Vaughan, M Ashton-Key, EL Williams, SV Dixon, HTC Chan, ...
Blood, The Journal of the American Society of Hematology 118 (9), 2530-2540, 2011
CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts
HTC Chan, D Hughes, RR French, AL Tutt, CA Walshe, JL Teeling, ...
Cancer research 63 (17), 5480-5489, 2003
CD20 as a target for therapeutic type I and II monoclonal antibodies
SA Beers, CHT Chan, RR French, MS Cragg, MJ Glennie
Seminars in hematology 47 (2), 107-114, 2010
The system can't perform the operation now. Try again later.
Articles 1–20